This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

FDA Approves Revised Alphanate® Labeling To Include Reduced Infectivity Of An Experimental Model Agent For VCJD

BARCELONA, Spain, March 4, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it received approval from the US Food and Drug Administration (FDA) for revised labeling for Alphanate ® Antihemophilic Factor/von Willebrand Factor Complex (Human) indicating that certain manufacturing steps have been shown to reduce the infectivity of a experimental TSE agent that is a model for variant Creutzfeldt Jakob Disease (vCJD).  The labeling revisions stem from extensive Grifols research into the capacity for various manufacturing steps to eliminate a TSE experimental model agent.  Data supporting the revised labeling was the result of work done in Grifols' research and development laboratories and was published in 2009 in the peer-reviewed journal Haemophilia, the official journal of the World Federation of Hemophilia (1).

(Logo:   http://photos.prnewswire.com/prnh/20110304/PH59473LOGO )

"This is the result of years of research, significant investment, and most importantly the dedication of many Grifols scientists," said Juan Ignacio Jorquera, Ph.D., the Director of Research and Development at Grifols.  "The potential of vCJD transmission by blood or blood products has been an area of substantial inquiry among global health authorities for more than a decade and we are proud to reach this important milestone," continued Dr. Jorquera.  Alphanate ® is the first plasma-derived blood clotting factor product to receive FDA-approved revised labeling that recognizes that manufacturing steps adopted by the company "provide reasonable assurance that low levels of CJD/vCJD agent infectivity, if present in the starting material, would be removed."  

"Because of our history, the bleeding disorders community has a responsibility to be informed and vigilant about the safety of the medicines we take," said Val Bias, CEO of the National Hemophilia Foundation. "It is encouraging to know that Grifols shares this responsibility with the community and is actively engaged in demonstrating the safety of their products," continued Mr. Bias.

In 2007 Alphanate ® became the first dual virus inactivated (heat treatment and solvent detergent) and affinity chromatography purified clotting factor complex approved for the treatment of von Willebrand Disease (VWD) and hemophilia A. Some of the same manufacturing processes that are proven effective at eliminating viruses also have demonstrated the ability to remove the CJD/vCJD experimental agent. Specific manufacturing steps with infectivity reduction capacity include polyethylene glycol precipitation, affinity chromatography and saline precipitation.

Grifols' research used two different experimental agent preparations as well as Western blot and bioassay detection methods.  Validated scale models of the production steps for both Alphanate ® and Grifols' Fanhdi ® (FVIII/VWF complex product marketed outside the United States) were used in the studies.  The combined effect of the production steps provided an imputed reduction capacity of 8 log 10 of the experimental CJD/vCJD agent.  

(1) DIEZ, J. M., CABALLERO, S., BELDA, F. J., OTEGUI, M., GAJARDO, R. and JORQUERA, J. I.  Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate®/Fanhdi®, a human factor VIII/VWF complex concentrate. Haemophilia 2009, 15: (6), 1249-1257.

About Alphanate®

Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate®, is indicated for the prevention and control of bleeding in patients with Factor VIII deficiency due to hemophilia A.  Alphanate®, is also indicated for surgical and/or invasive procedures in adult and pediatric patients with von Willebrand Disease, except Type III undergoing major surgery, in whom desmopressin (DDAVP®) is either ineffective or contraindicated.  Antihemophilic factor potency (Factor VIII:C activity) is expressed in International Units (IU) on the product label.  Additionally, each vial of Alphanate® also contains VWF:RCo activity in IU for the treatment of VWD.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs